DATASCOPE RECEIVES EUROPEAN APPROVAL TO MARKET

                 First Anti-Microbial Vascular Graft 

MONTVALE, N.J., April 13 /PRNewswire/ -- Datascope Corp. (Nasdaq: DSCP) announced that InterVascular, Inc., its wholly owned subsidiary, has received the CE Mark for its InterGard(R) Silver anti-microbial vascular graft. Vascular grafts are used to replace diseased arteries. With this approval, the company can begin commercial sale of the world's first anti-microbial vascular graft throughout Europe. The InterGard Silver was launched at the European Vascular Congress meeting in Marseille, France in late March and is expected to begin shipping this month.

The InterGard Silver graft is designed to prevent postoperative infection of the graft. The incidence of prosthetic graft infections is estimated to be in the range of 2-5% and such infections are associated with high morbidity including amputation and high mortality. Infection also typically prolongs the hospital stay of a patient by 50 days which corresponds to an increase of $50,000 in cost. The InterGard Silver graft is designed to prevent infection by using the broad spectrum, anti-infective properties of silver which is released from the surface of the graft to surrounding tissues following implantation.

In the fiscal year ended June 1998, InterVascular sales of $18.9 million accounted for 8% of Datascope's sales. European sales for vascular grafts in fiscal year 1998 approximated $13 million or 13% of the market. Based on initial customer response, Datascope believes the InterGard Silver will strengthen InterVascular's competitive position, command a premium price and increase market share.

Datascope Corp. is a diversified medical device company that manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care.

This press release contains forward-looking statements that involve
risks and uncertainties, particularly relating to the ability of the
company to successfully introduce and gain market acceptance for new
products, as well as other risks detailed from time to time in
documents filed by Datascope with the Securities and Exchange
Commission.
SOURCE Datascope Corporation

-0-                             04/13/99 /CONTACT:  Murray Pitkowsky, 
Senior Vice President of Datascope Corp., 201-307-5504/ 

(DSCP)
CO: Datascope Corporation; InterVascular, Inc. ST: New Jersey IN:
HEA MTC SU: PDT